Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Ferritin & ALC Predict PFS in Myeloma Bispecific Antibody Therapy | Tarek Mouhieddine, MD #IMS25
HealthTreeDescription
Can simple blood markers like ferritin and absolute lymphocyte count (ALC) help predict how well myeloma patients respond to CAR-T cell therapy or bispecific antibodies? In this HealthTree video, we explore the latest research on how these biomarkers may forecast progression-free survival (PFS). Learn why ferritin, a marker of inflammation, and ALC, a measure of immune strength, are being studied as tools to guide treatment decisions and outcomes in multiple myeloma.
If you’re interested in understanding how lab values connect to the future of myeloma immunotherapy, this is a must-watch!
#Myeloma #CART #Bispecifics #Biomarkers #Ferritin #ALC
Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree Cure Hub here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.